Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA

Archives of Dermatological Research

Volumn 288, Issue 9, 1996, Pages 543-548

  Rajan, G P ^a   Seifert, B ^a   Prummer O ^b   Joller Jemelka, H I ^a   Burg, G ^a   Dummer, R ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Anti interferon antibodies; Cutaneous T cell lymphoma; PUVA; Retinoid; Therapy

Indexed keywords

ANTI ACNE AGENT; ANTIPSORIASIS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; ETRETIN; INTERFERON ANTIBODY; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METHOXSALEN; NEOPTERIN; RECOMBINANT ALPHA2A INTERFERON;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PUVA; SKIN LYMPHOMA; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

EID: 0029760969     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02505252     Document Type: Article

References (27)

1. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G (1993) Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 13 : 121-125
2. Bunn PJ, Hoffman SJ, Norris D, Golitz LE, Aeling JL (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121 : 592-602
3. Dianzani F, Antonelli G, Capobianchi MR (1990) The biological basis for clinical use of Interferon. J Hepatol 11[Suppl 1] : S5-10
4. Dreno B (1993) Roferon-A (Interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells (Dayt) 11 : 269-275
5. Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-β, but not against interferon-γ during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67 : 2300-2304
6. Dummer R, Nestle F, Wiede J, Schäfer E, Roger J, Erhard H, Hefner H, Burg G (1991) Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas. Eur J Dermatol 1 : 135-138
7. Dummer R, Kohl O, Gillisson J, Kägi M, Burg G (1993) Peripheral blood mononuclear cells in non-leukemic cutaneous T-cell lymphoma patients: reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch Dermatol 129 : 433-436
8. Edelson RL (1980) Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 2 : 89-106
9. Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29 : 307-341
10. Gilmour JW, Vestey JP, Norval M (1993) The effect of UV therapy on immune function in patients with psoriasis. Br J Dermatol 129 : 28-38
11. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M (1991) Treatment of cutaneous T cell lymphoma with a combination of low-dose Interferon alfa-2b and retinoids. J Am Acad Dermatol 24 : 247-252
12. Kuzel TM, Roenigk HJ, Rosen ST (1991) Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy. J CLin Oncol 9 : 1298-1313
13. Kuzel TM, Roenigk HJ, Samuelson E, Rosen ST (1992) Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 84 : 119-121
14. Laskin JD, Mermelstein FH, Heindel ND, Ron Y (1993) Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J Leukoc Biol 54 : 138-144
15. Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM (1987) Alfa-2b Interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 14 : 18-23
16. Mostow EN, Neckel SL, Oherhelman L, Anderson TF, Cooper KD (1993) Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129 : 747-752
17. Oberg K (1989) Antibodies in carcinoid syndrome. J Natl Cancer Inst 81 : 531-535
18. Papa G, Tura S, Mandelli F, Vegna ML, Detazio D, Mazza P, Zinzani PL, Simoni R, DePita O, Ferranti G, et al (1991) Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 48 : 48-51
19. Peakman M, Vergani D (1994) Autoimmune disease: etiology, therapy and regeneration. Immunol Today 15 : 345-347
20. Prummer O (1993) Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant imerferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 71 : 1828-1834
21. Quesada JR, Rios A, Swanson D, Tworn P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3 : 1522-1528
22. Roenigk H, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PJ, et al (1990) Photochemotherapy alone or combined with Interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 : 198S-205S
23. Romagnani S (1992) Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98 : 279-285
24. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant Interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318 : 1409-1413
25. Wussow P von, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-alpha antibody titres during Interferon therapy (letter). Lancet 2 : 635-636
26. Wussow P von, Jakschies D, Freund M, Deicher H (1989) Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J Interferon Res 9 [Suppl] : S25-31
27. Zachariae H, Thestrup-Pedersen K (1990) Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 : 206S-208S